NYSEHealth CarePharmaceutical PreparationsTEL AVIV - YAFO, Israel

Nasus Pharma Ltd. NSRX

Ask your AI

Estimated market cap $25.87M9.02M shares, shares as of Dec 31, 2025CIK 2029039

Insider trades, 12 mo

3 buys · 0 sells

$61.8K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

1 added · 0 trimmed

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in Nasus Pharma Ltd.'s latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

3 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jun 17, 2026. Insiders have two business days to file.

Recent insider trades

Dan Benjamin Teleman Chief Executive Officer, Director	Jun 17 Form 4 ↗	Buy	+$20.3K 6,550 sh @ $3.10	-8.6%
Dan Benjamin Teleman Chief Executive Officer, Director	Apr 22 Form 4 ↗	Buy	+$10.9K 2,900 sh @ $3.76	-32.3%
Dan Benjamin Teleman Chief Executive Officer, Director	Mar 31 Form 4 ↗	Buy	+$30.6K 15,000 sh @ $2.04	+13.3%

All NSRX insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

240,223 shares

5 funds report NSRX. Values checked against market prices.

Funds own 24% of shares (Q2 2026)

10 funds hold the stock.

Q3 2026: 2.7% · 5,560 of ~8,900 funds reported so far

Q3 2025<0.1%
Q4 2025<0.1%
Q1 202624%
Q2 202624%
Q3 2026 (so far)2.7%

Q3 2026. 0 new, 1 added to, 0 trimmed, 5 exited since Q2 2026.

Top 13F holders
#
1	Hudson Bay Capital Management LP 13F ↗	134,771	$497.3K	unchanged
2	Bleichroeder LP 13F ↗	89,848	$331.5K	unchanged
3	Renaissance Technologies LLC 13F ↗	14,600	$53.9K	+19.7%
4	Morgan Stanley 13F ↗	1,000	$3,690	unchanged
5	Caitong International Asset Management Co., Ltd 13F ↗	4	$15	unchanged

Download CSV Every fund that holds NSRX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Nasus Pharma Ltd. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Nasus Pharma Ltd. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2025	2	—	3,241	$21.6K
Q4 2025	2	0	2,378	$21.8K
Q1 2026	9	+7	2.17M	$4.8M
Q2 2026	10	+1	2.15M	$7.5M
Q3 2026	5	-5	240,223	$886.4K

Each point is a quarter-end, from Q3 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (M7071P109). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes3 in 12 mo 8-K eventsNone in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials3 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Nasus Pharma Ltd
Address: 29 HARAKEVET ST, TEL AVIV - YAFO, Israel 6618003
Phone: 972 54-255-3956
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, emerging growth company
Incorporated in: Israel
Listed as: NSRX (NYSE)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$2.87+$0.05 (+1.77%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $2.82 · High $3.49Nov 13, 2026

Aug 13, 2026Low $2.82 · High $4.10Nov 13, 2026

Nov 13, 2025Low $2.01 · High $9.15Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.